The Development and Validation of a Novel Designer Benzodiazepines Panel by LC–MS-MS

Abstract Novel illicit benzodiazepines are among the most active areas of new drug manufacture and use. We describe a method for detection quantification etizolam its metabolite α-hydroxyetizolam, flubromazolam, clonazolam, diclazepam, delorazepam, bromazepam, flubromazepam, phenazepam, flualprazolam, flunitrazolam, nitrazolam in human whole blood. After addition internal standards, samples buffered extracted using liquid–liquid extraction. Analysis is performed positive-ion electrospray tandem mass spectrometry quantitation. Calibration ranges were established based on performance differed from compound to compound. Replicates at lowest calibration point each within 5% CV (Coefficient Variation). The correlation coefficient was >0.990 all compounds. Relative standard deviation compounds ≤10% accuracy ±10% both within- between-run experiments. maximum average intra- inter-run imprecision 5.7%. −8.7%. As part evaluating scope relevancy, testing positive immunoassay but confirmed be negative traditional benzodiazepine confirmation re-analyzed this method. presence least one novel identified 70% these samples. appearance “designer” demonstrates challenge toxicology need continually updated methods.